Ophthalmology Drugs Global Market Report 2018

1
Ophthalmology Drugs Global Market Report 2018
Including Antiglaucoma Drugs Dry Eye
Medication Other Ophthalmological
Drugs Covering Novartis AG, F. Hoffmann-La
Roche Ltd., Allergan Plc, Valeant
Pharmaceuticals Intl Inc., Bayer AG
Feb 2018
2
Reasons to Purchase

• Outperform competitors using accurate up to date
  demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of
  historic and forecast data and the drivers and
  restraints on the market.
• Create regional and country strategies on the
  basis of local data and analysis.
• Stay abreast of the latest customer and market
  research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future
  developments.
• Utilize the relationships between key data sets
  for superior strategizing.
• Suitable for supporting your internal and
  external presentations with reliable high
  quality data and analysis
• Gain a global perspective on the development of
  the market.
• Report will be updated with the latest data and
  delivered to you within 3-5 working days of
  order.
• Scope
• Markets Covered Antiglaucoma Drugs Dry Eye
  Medication Other Ophthalmological
• Drugs
• Companies Mentioned Novartis AG, F. Hoffmann-La
  Roche Ltd., Allergan Plc, Valeant
  Pharmaceuticals Intl Inc., Bayer AG
• Countries Brazil, China, France, Germany, India,
  Italy, Japan, Spain, Russia, UK, USA and
  Australia.
• Regions Asia-Pacific, Western Europe, Eastern
  Europe, North America, South America, Middle
  East And Africa

3
Ophthalmology Drugs Market Characteristics
The ophthalmology drugs market covers drugs that
are used in the treatment of eye related
diseases such as refractive errors, cataracts,
glaucoma, conjunctivitis, retinal diseases, and
macular degeneration. Some of the major
ophthalmic drugs include Eylea, Lucentis,
Restasis, Vigamox, Azopt, and Lotemax. The market
numbers in this briefing cover pharmaceutical
(drug) treatments and do not cover biologic
treatments for these conditions which are
included in a separate briefing. This market is
further classified as follows Anti-glaucoma
drugs are used for the treatment of glaucoma, a
disease that Dry Eye Medications include drugs
to Other Ophthalmological Drugs These include
drugs for
In this report market value is defined as the
revenues organizations earn by selling their
goods and services within the specified market,
based on the price at which they sell. Only
goods and services traded between entities are
included. The revenues for a specified geography
are consumption values that is, they are
revenues generated by organizations in the
specified geography within the specified
market, irrespective of where they are produced.
4
Ophthalmology Drugs Market Historic Growth
The global ophthalmology drugs market grew from
X billion in 2013 to X billion in 2017 at a
compound annual growth rate (CAGR) of X. The
chart and table below shows the year-on-year
growth of the global ophthalmology drugs market
during 2013 2017.
Drivers of the Market Restraints on the Market
5
Ophthalmology Drugs Market Forecast Growth
The global ophthalmology drugs market is expected
to grow from XX billion in 2017 to 36.3
billion in 2021 at a compound annual growth rate
(CAGR) of XX. This can be attributed to the
expected rise in prevalence of eye conditions
such as age-related macular degeneration (AMD),
diabetic retinopathy and glaucoma that require
ophthalmology drugs. The chart and table below
shows the year-on-year growth of the global
ophthalmology drugs market during 2017 - 2021.
Drivers of the Market Restraints on the Market
6
Ophthalmology Drugs Market Segmentation
The chart and table below shows the split of the
ophthalmology drugs market in 2017.
The total market value for ophthalmology drugs
was X billion in 2017. The markets that are
covered include Antiglaucoma Drugs Dry Eye
Medication Other Ophthalmological
Drugs. Antiglaucoma Drugs was the X largest
segment in the ophthalmology drugs market with
X share of the market. The market value for the
antiglaucoma drugs was X billion in 2017. Dry
Eye Medication made up around X share of the
market. The market value for the dry eye
medication was X billion in 2017.
7
Ophthalmology Drugs Market Regional And Country
Analysis
The Asia Pacific was the largest region in the
ophthalmology drugs market in 2017,
ophthalmology drugs for X billion or X market
share. North America was the x largest region
ophthalmology drugs for X billion or X market
share. Western Europe was the x largest region
ophthalmology drugs for X billion or X market
share.
8
Ophthalmology Drugs Market Competitive Landscape
The leading competitors in the global
ophthalmology drugs market are Novartis AG, F.
Hoffmann-La Roche Ltd., Allergan Plc, Valeant
Pharmaceuticals Intl Inc., Bayer AG. The chart
and table below displays the percentage market
share of the top players in the ophthalmology
drugs market industry.
Novartis AG generated revenues of XX billion for
the financial year 2016, an XX decrease from
the previous year. F. Hoffmann-La Roche Ltd.
generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year. Allergan Plc. generated revenues
of XX billion for the financial year 2016, an
XX increase from the previous year. Valeant
Pharmaceuticals Intl Inc. generated revenues of
XX billion for the financial year 2016, an XX
increase from the previous year.
9
Bayer AG generated revenues of XX billion for
the financial year 2016, an XX increase from
the previous year. Santen Pharmaceutical Co.,
Ltd. generated revenues of XX billion for the
financial year 2016, an XX increase from the
previous year. Gilead generated revenues of XX
billion for the financial year 2016, an XX
decrease from the previous year. Otsuka
Pharmaceutical Co., Ltd. generated revenues of
XX billion for the financial year 2016, an XX
decrease from the previous year. Shire Plc.
generated revenues of XX billion for the
financial year 2016. Company Profile Novartis
AG Overview Novartis AG was the largest
competitor in the ophthalmology drugs market in
2017 with a XX share of the market.
Novartis is a multinational pharmaceutical comp
any that develops, manufacture and markets
healthcare products. The company was founded in
1970 and is headquartered in Basel,
Switzerland. Products and Services The company
operates through the following divisions The
Innovative Medicines division focuses on The
Alcon division focuses on the The Sandoz
division focuses on
10
Strategy Novartis growth strategy is to focus on
strengthening its ophthalmology pipeline through
acquisitions. In December 2016, the company
acquired pharmaceutical company Encore Vision,
Inc. that develops treatment for presbyopia, an
ophthalmologic disorder. In addition, Novartis
is Financial Performance Novartis Ophthalmology
division, involved in ophthalmology drugs
manufacturing, generated revenues of XX billion
for the financial year 2016, a XX decrease from
the previous year. The company had a market F.
Hoffmann-La Roche Ltd. Overview Products and
Services Strategy Financial Performance Allergan
Plc Overview Products and Services
Strategy Financial Performance Valeant
Pharmaceuticals Intl Inc. Overview Products and
Services Strategy Financial Performance Bayer
AG Overview Products and Services
Strategy Financial Performance